A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer

Cancer Chemotherapy and Pharmacology
N J MeropolP J Creaven

Abstract

A phase I and pharmacokinetics study of oral uracil, ftorafur, and leucovorin was performed in patients with advanced cancer. Uracil plus ftorafur (UFT) was given in a 4:1 molar ratio in three divided doses for 28 consecutive days. Patient cohorts were treated at 200, 250, 300, and 350 mg/m2 of UFT daily. For all patients, 150 mg of leucovorin was given daily in three oral doses. A 1-week rest period followed each 28-day treatment course. Gastrointestinal toxicity, characterized by diarrhea, nausea, and vomiting, was dose-limiting at 350 mg/m2 UFT in patients who had received prior chemotherapy. Mild fatigue and transient hyperbilirubinemia were also common. In previously untreated patients, UFT at 350 mg/m2 was well-tolerated, suggesting this as an acceptable phase II dose in this schedule with leucovorin. Two of eight previously untreated patients with advanced colorectal cancer had partial responses with UFT (350 mg/m2) plus leucovorin. Pharmacokinetic parameters [ftorafur, uracil, 5-fluorouracil (5-FU), 5-methyltetrahydrofolate] showed wide interpatient variations. Plasma levels of 5-FU (Cmax 1.4 +/- 1.9 microM) were comparable to those achieved with protracted venous infusions, and folate levels (Cmax 6.1 +/- 3.6 microM) w...Continue Reading

Citations

Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Brian G CzitoHerbert I Hurwitz
Oct 19, 1999·International Journal of Radiation Oncology, Biology, Physics·A de la TorreG Aragón
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N J Meropol
Dec 16, 2003·Breast Cancer Research and Treatment·Anne-Renee HartmanFrank E Stockdale
Feb 3, 2005·American Journal of Clinical Oncology·Supriya GuptaUNKNOWN University of Chicago Phase II Network
Apr 7, 2007·American Journal of Clinical Oncology·Basil F El-RayesPhilip A Philip
May 14, 2009·Therapeutics and Clinical Risk Management·Pasquale ComellaLuca Franco
Mar 13, 2002·Drugs & Aging·K Wellington, K L Goa
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M L VeroneseP J O'Dwyer
Dec 7, 2000·Cancer Investigation·N L Lewis, N J Meropol
Mar 13, 2003·British Journal of Clinical Pharmacology·Ronald GieschkeJean-Louis Steimer
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Karen L TedescoBapsi Chakravarthy
Jun 16, 2001·Current Problems in Cancer·C H Takimoto
Mar 16, 2001·Expert Opinion on Pharmacotherapy·A GelmannS A Waldman
Oct 5, 2001·Expert Opinion on Pharmacotherapy·R Jones, C Twelves
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Yves DouillardSteven E Benner
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James CarmichaelChristophe Martin
Feb 25, 2000·Journal of the American Academy of Dermatology·T KonoS Taniguchi
Feb 24, 2005·Journal of Surgical Oncology·Ling-Wei WangSang-Hue Yen
May 5, 2000·The Oncologist·S Sharma, L B Saltz
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L BlumT Griffin
Oct 16, 1999·American Journal of Clinical Oncology·J S Macdonald
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M HoffR Pazdur
Feb 24, 2001·The Annals of Pharmacotherapy·J G Kuhn

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.